We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Braveheart Investment Group Plc | LSE:BRH | London | Ordinary Share | GB00B13XV322 | ORD 2P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.50 | -9.09% | 5.00 | 4.00 | 6.00 | 5.50 | 5.00 | 5.50 | 263,101 | 09:20:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Management Services | 51k | 1.59M | 0.0249 | 2.01 | 3.19M |
From Nov 2023 to May 2024
TIDMBRH
RNS Number : 9734U
Braveheart Investment Group plc
29 November 2023
29 November 2023
Braveheart Investment Group plc
("Braveheart" or the "Company")
Investment update - Paraytec Limited
Braveheart Investment Group (AIM: BRH), provides the following update on Paraytec Limited ("Paraytec"), a company within its investment portfolio. Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation markets.
Paraytec has informed Braveheart that it has secured its first commercial sales contract for the CX300 Optical Particle detector instrument (the "CX300 instrument"), to Nottingham Trent University ("NTU"). The instrument will be installed in the "EX-Cell group" at NTU, led by Prof Elisabetta Verderio Edwards, who's work focuses on the role of extracellular factors in cell survival in conditions of neurodegeneration and tissue repair. The CX300 instrument will be used to further their Alzheimer's, Dementia and Parkinson's research at NTU.
The Directors of Paraytec believe that this sale of the CX300 instrument could be the first of many to UK and European research laboratories.
Trevor Brown, CEO of Braveheart, commented:
"This sales contract with NTU is the first commercial sale of the CX300 instrument by Paraytec, justifying our investment in the company and its development in the CX300 instrument, as well as Paraytec's continuing commitment to innovation."
Braveheart holds a 100% equity interest in Paraytec. In addition, Braveheart has provided unsecured interest free loans to Paraytec totalling GBP1,155,200 as at 31 March 2023.
For further information:
Braveheart Investment Group plc Tel: 01738 587555 Trevor Brown CEO Allenby Capital Limited (Nominated Adviser Tel: 020 3328 5656 and Joint Broker) James Reeve / George Payne Peterhouse Capital Limited (Joint Broker) Tel: 020 7469 0936 Duncan Vasey / Lucy Williams
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
UPDBIBDBLUDDGXI
(END) Dow Jones Newswires
November 29, 2023 02:00 ET (07:00 GMT)
1 Year Braveheart Investment Chart |
1 Month Braveheart Investment Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
